Glaxosmithkline's First Patent on Imitrex Is Scheduled to Expire In July 2007 - 'Outlook for the Migraine Market: With Novel Approaches Limited, Triptans Dominate'.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47716) has announced the addition of Outlook for the Migraine Market: With Novel Approaches Limited, Triptans Dominate to their offering.

The treatment of migraine is an underserved, underdiagnosed market with great growth potential. Despite the current dominance of triptan therapies, the upcoming entrance of new formulations and new applications of existing treatments, as well as the introduction of new therapeutic agents, will likely substantially alter the market.

Get the Answers You Need to Shape Your Strategy:

No significantly new treatment for migraine has been launched since the advent of the 5-HT1 agonists, also known as triptans. Are there other potentially effective treatments on the horizon? What effect could new treatments have on the current market? Two areas of migraine treatment exist: prophylactic, which seeks to prevent the occurrence of migraine, and abortive, which treats the symptoms of migraine after they have begun. What room for growth does each of these treatment areas contain? Which area holds the most growth potential? What are some of the roadblocks to new treatment development? GlaxoSmithKline's first patent on Imitrex is scheduled to expire in July 2007. What effect will this have on the market? What products are poised to enter the market? What is GSK doing to protect its current market dominance? What can other companies do to take advantage of this imminent patent expiration?

Scope:

Migraine background: Symptoms, triggers, etiology, and possible implicated neurotransmitters.

Patient population: Size and makeup of migraine patient populations worldwide.

Current approaches to migraine treatment: Current migraine treatments; their mechanisms of action; characteristics such as onset of action and duration of action, efficacy, and side effects; and the factors influencing treatment choice.

Current market: Current migraine market, both domestic and international.

Emerging migraine therapies: New formulations of and delivery systems for existing drugs and the development of new agents. Timetable for testing and market entry for each emerging therapy.

Market outlook: The near future for markets in the United States, Europe, and Japan; factors that will affect the market; and possible future scenarios.

Content Outline:

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

An Overview of Migraine

Etiology and Pathophysiology

Symptoms and Triggers

Epidemiology

Current Treatment

Abortive Treatments

Triptans

Ergot Derivatives

Prophylactic Therapies

Beta Blockers

NSAIDS

Antiepileptic Agents

Antidepressants

5-HT Antagonists

Current Market

Emerging Agents

Abortive Therapies

Pozen and GSK's Trexima

NovaDel's Sublingual Sumatriptan

Zogenix's Subcutaneous Sumatriptan

Alexza's Prochlorperazine

ProEthic's Diclofenac

Pozen's Lornoxicam

GlaxoSmithKline's 274150

GlaxoSmithKline's 705498

Boehringer Ingelheim's Olcegepant

Prophylactic Therapies

Ariston's AST-726

Minster Pharmaceutical's Tonabersat

TorreyPines Therapeutics' Tezampanel

Eisai's E-2007

Winston's Zucapsaicin

Market Outlook

New Opportunities in the Migraine Market

Generic Threats

Outlook to 2010

Tables
1. Neurotransmitters and Biochemicals Implicated in Migraine Attacks
2. Leading Branded Prescription Treatments for Migraine, 2005
3. Products in Clinical Development for the Treatment of Migraine

Figures
1. Select Precipitating (Triggers) Factors Associated with Migraine
2. Time Course of Migraine Symptom Intensity and Recommended
   Treatments
3. Worldwide Triptan Market, 2005

Companies Mentioned in this Spectrum Report:

-         Abbott
-         Alexza
-         Almirall
-         Applied Pharma Research
-         Aradigm
-         Ariston
-         AstraZeneca
-         Bayer
-         Boehringer Ingelheim
-         Cobalt Pharmaceuticals
-         Dr. Reddy's Laboratories
-         Eisai
-         Elan
-         Endo Pharmaceuticals
-         GlaxoSmithKline
-         Johnson & Johnson
-         Kyorin
-         Menarini
-         Merck
-         Minster Pharmaceutical
-         Mylan
-         NovaDel
-         Novartis
-         Organon
-         Pierre Fabre
-         Pfizer
-         Pozen
-         ProEthic
-         Ranbaxy
-         Roche
-         Schwarz Pharma
-         Spectrum Pharmaceuticals
-         Torrey Pines Therapeutics
-         Valeant Pharmaceuticals
-         Vernalis
-         Winston
-         Wyeth
-         Zogenix

For more information visit http://www.researchandmarkets.com/reports/c47716

Source: Decision Resources